• HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IL-28B protein

Activity

0.07-0.35 ng/mL EC50

Species Reactivity

human

Purity

>95%

Cat no : HZ-1245

Synonyms

Cytokine Zcyto22, IFN lambda 3, IFN lambda 4, IFNL3, IFNL4, IFN-lambda 3, IFN-lambda 4, IL 28B, IL 28C, IL28, IL-28, IL28B, IL-28B, IL28C, Interferon lambda 3, Interferon lambda 4, Interleukin 28B, Interleukin 28C, ZCYTO22



Technical Specifications

GeneID 282617
Species Human
Expression HEK293
Activity 0.07-0.35 ng/mL EC50
Purity >95%
Endotoxin<1 EU/μg
Accession NumberQ8IZI9
Molecular Mass 24 kDa, monomer, non-glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human

Stability and Reconstitution

Stability and StorageProduct FormTemperature ConditionsStorage Time
(From Date of Receipt)
Lyophilized-20°C to -80°CUntil Expiry Date
LyophilizedRoom Temperature2 weeks
Reconstituted as per CofA-20°C to -80°C6 months
Reconstituted as per CofA4°C1 week
Avoid repeated freeze-thaw cycles.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile 1xPBS containing 0.1% endotoxin-free recombinant human serum albumin (HSA).

Background

IL28B is a type III IFN, which shares many of the biological effects of type I IFNs but may have fewer side effects due to a more selective receptor distribution. It interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha (IL28RA) (PMID: 20712453;12469119;16539846).

Synonyms

Cytokine Zcyto22, IFN lambda 3, IFN lambda 4, IFNL3, IFNL4, IFN-lambda 3, IFN-lambda 4, IL 28B, IL 28C, IL28, IL-28, IL28B, IL-28B, IL28C, Interferon lambda 3, Interferon lambda 4, Interleukin 28B, Interleukin 28C, ZCYTO22

Publications

SpeciesTitle
human

J Virol Methods

Screening of novel drugs for inhibiting hepatitis E virus replication.

Authors - Takashi Nishiyama
human

Cytokine

IFN-λ3 as a host immune response in acute hepatitis E virus infection.

Authors - Kazumoto Murata

Antiviral Res

Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.

Authors - Takashi Nishiyama